TY  - CONF

T1  - Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with ErbB2+(HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective

JO  - EJC SUPPLEMENTS

PY  - 2007/09/01

AU  - Delea TE

AU  - Tappenden P

AU  - Sofrygin O

AU  - Karnon J

AU  - Amonkar M

AU  - Browning D

AU  - Rudge H

AU  - Walker M

ED  - 

VL  - 5

IS  - 4

SP  - 225

EP  - 225

Y2  - 2024/12/21

ER  -